Deltex Medical sees blood flow monitor sales double
Deltex Medical, the makers of a device which monitors blood flow during and after operations, says it is beginning to benefit from an official recommendation by the National Institute for Health and Clinical Excellence (NICE).
Deltex Medical, the makers of a device which monitors blood flow during and after operations, says it is beginning to benefit from an official recommendation by the National Institute for Health and Clinical Excellence (NICE).
In March last year NICE recommended that the CardioQ-ODM system be considered for use in all patients undergoing major and high risk surgery in the NHS. Since December Deltex has seen a 40% increase in sales of its surgical probes compared to the prior year.
The firm still awaits the adoption of ODM as one of six "high impact" technologies to be implemented in the NHS but is pinning its hopes on a report to be published this Summer which may give the official stamp of approval.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
By 11:30 the stock had risen 2.7%.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
University tuition fees will rise to £9,535 next year – what does it mean for you?
The tuition fee hike has angered many students, not to mention their parents and grandparents who often help with financial support. But will it make a difference to how much you repay in the long run?
By Katie Williams Published
-
Will platinum and palladium rise?
Analysis Platinum and palladium have lagged gold and silver recently, but the outlook is improving. Should you invest?
By David J. Stevenson Published